Platelet kinetics in patients with atherosclerosis.
In 12 patients (8 males, 4 females; 59.4 +/- 6.2 years) with clinically manifest atherosclerosis (peripheral vascular disease stage II according to Fontaine and coronary heart disease) without any risk factor and 6 controls (4 males, 2 females; 58.5 +/- 7.06 years) autologous platelets were labelled using 100 microCi 111-In-oxine. In parallel, serum- and plasma-thromboxane (TX) B2 and conversion of exogenous radiolabelled arachidonic acid towards TXB2 were determined. No difference in labelling efficiency and recovery was noted. Platelet half-life was significantly (p less than 0.01) shortened in the atherosclerotics. Gamma-camera images were obtained during the first 64 minutes after reinjection as well as 2, 6, 18, 24 and daily up to 1 week after reinjection of autologous radiolabelled platelets. No difference between the patients suffering from atherosclerosis--having either visible atherosclerotic lesions or not--could be discovered. Serum-TXB2 was comparable, whereas plasma-TXB2 showed a trend towards an increase and the conversion from exogenous 14C-AA to 14C-TXB2 was increased in atherosclerosis.
Sinzinger
H
H
Department of Nuclear Medicine, University of Vienna, Ludwig Boltzmann-Institute for Nuclear Medicine, Austria.
Virgolini
I
I
Fitscha
P
P
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001161:Arteriosclerosis / Q000097:blood* / Q000000981:diagnostic imaging; D001792:Blood Platelets / Q000473:pathology*; D002470:Cell Survival; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000096:biosynthesis; D011877:Radionuclide Imaging; D013929:Thromboxane B2 / Q000096:biosynthesis; D001620:beta-Thromboglobulin / Q000096:biosynthesis
D001095:Arachidonic Acids; D001620:beta-Thromboglobulin; D016718:Arachidonic Acid; D010978:Platelet Factor 4; D013929:Thromboxane B2